Next Article in Journal
The Credibility of Health Information Sources as Predictors of Attitudes toward Vaccination—The Results from a Longitudinal Study in Poland
Next Article in Special Issue
An Update on mRNA-Based Viral Vaccines
Previous Article in Journal
TBE Vaccination Breakthrough Cases—Does Age Matter?
Previous Article in Special Issue
Chlamydia trachomatis Cross-Serovar Protection during Experimental Lung Reinfection in Mice

In Vitro Priming of Human T Cells by Dendritic Cells Provides a Screening Tool for Candidate Vaccines for Burkholderia pseudomallei

Antigen Presentation Research Group, Imperial Centre for Translational and Experimental Medicine, 72 Du Cane Road, London W12 0NN, UK
Gut Microbes & Health Program, Quadram Institute Bioscience, Norwich NR4 7UQ, UK
St Mark’s Hospital, London North West University Healthcare NHS Trust, Harrow UT 84124, UK
Defence Science and Technology Laboratory, Porton Down SP4 0JQ, UK
Author to whom correspondence should be addressed.
Current Address: Parkinson’s UK, London SW1V 1EJ, UK.
Current Address: Mucosal Immunology Lab, Instituto de Biología y Genética Molecular (IBGM), University of Valladolid, 47002 Valladolid, Spain.
Current Address: Chelsea & Westminster Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.
Academic Editor: Steven B. Bradfute
Vaccines 2021, 9(8), 929;
Received: 24 June 2021 / Revised: 10 August 2021 / Accepted: 18 August 2021 / Published: 22 August 2021
(This article belongs to the Collection Vaccines against Infectious Diseases)
Murine dendritic cells, when pulsed with heat-killed Burkholderia pseudomallei and used to immunise naïve mice, have previously been shown to induce protective immunity in vivo. We have now demonstrated the in vitro priming of naïve human T cells against heat-killed B. pseudomallei, by co-culture with syngeneic B. pseudomallei-pulsed dendritic cells. Additionally, we have enriched the DC fraction such that a study of the differential response induced by pulsed DCs of either myeloid or plasmacytoid lineage in syngeneic human T cells was achievable. Whilst both mDCs and pDCs were activated by pulsing, the mDCs contributed the major response to B. pseudomallei with the expression of the migration marker CCR7 and a significantly greater secretion of the proinflammatory TNFα and IL1β. When these DC factions were combined and used to prime syngeneic T cells, a significant proliferation was observed in the CD4+ fraction. Here, we have achieved human T cell priming in vitro with unadjuvanted B. pseudomallei, the causative organism of melioidosis, for which there is currently no approved vaccine. We propose that the approach we have taken could be used to screen for the human cellular response to candidate vaccines and formulations, in order to enhance the cell-mediated immunity required to protect against this intracellular pathogen and potentially more broadly against other, difficult-to-treat intracellular pathogens. To date, the polysaccharide capsule of B. pseudomallei, fused to a standard carrier protein, e.g., Crm, looks a likely vaccine candidate. Dendritic cells (DCs), providing, as they do, the first line of defence to infection, process and present microbial products to the immune system to direct downstream immune responses. Here, we have sought to use DCs ex vivo to identify immunogenic products from heat-killed B. pseudomallei. Using practical volumes of fresh human donor blood, we show that heat-killed B. pseudomallei activated and stimulated the expression of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 from both myeloid and plasmacytoid DCs. Furthermore, B. pseudomallei-pulsed DCs cultured with naïve syngeneic T cells ex vivo, induced the activation and proliferation of the CD4+ T-cell population, which was identified by cell surface marker staining using flow cytometry. Thus, both DC subsets are important for driving primary T helper cell responses to B. pseudomallei in healthy individuals and have the potential to be used to identify immunogenic components of B. pseudomallei for future therapies and vaccines. View Full-Text
Keywords: dendritic cells; Burkholderia pseudomallei; T cell priming dendritic cells; Burkholderia pseudomallei; T cell priming
Show Figures

Figure 1

MDPI and ACS Style

Reddi, D.; Durant, L.; Bernardo, D.; Noble, A.; English, N.R.; Hendy, P.; Clark, G.C.; Prior, J.L.; Williamson, E.D.; Knight, S.C. In Vitro Priming of Human T Cells by Dendritic Cells Provides a Screening Tool for Candidate Vaccines for Burkholderia pseudomallei. Vaccines 2021, 9, 929.

AMA Style

Reddi D, Durant L, Bernardo D, Noble A, English NR, Hendy P, Clark GC, Prior JL, Williamson ED, Knight SC. In Vitro Priming of Human T Cells by Dendritic Cells Provides a Screening Tool for Candidate Vaccines for Burkholderia pseudomallei. Vaccines. 2021; 9(8):929.

Chicago/Turabian Style

Reddi, Durga, Lydia Durant, David Bernardo, Alistair Noble, Nicholas R. English, Philip Hendy, Graeme C. Clark, Joann L. Prior, Ethel D. Williamson, and Stella C. Knight 2021. "In Vitro Priming of Human T Cells by Dendritic Cells Provides a Screening Tool for Candidate Vaccines for Burkholderia pseudomallei" Vaccines 9, no. 8: 929.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop